Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Charles River Laboratories (CRL) · oqro.io/stocks/CRL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Traded Aug 6 · filed 4 days laterNot reported under a pre-arranged trading plan
Since the trade +23.5% · S&P 500 −6.9% · to Nov 19
Charles River Laboratories's & Chief People Officer sold $1.08M of Charles River Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Traded Aug 22, 2025 · filed 151 days laterNot reported under a pre-arranged trading plan
Since the trade +102.6% · S&P 500 +10.9% · to Nov 19
Charles River Laboratories's Corp Strategy & Develop sold $65K of Charles River Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Traded Aug 18, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade +108.9% · S&P 500 +11.3% · to Nov 19
Charles River Laboratories's Corp Strategy & Develop sold $126K of Charles River Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Traded Aug 7, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +118.9% · S&P 500 +13.2% · to Nov 19
Charles River Laboratories's Corp Strategy & Develop sold $60K of Charles River Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Traded May 13, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade +127.7% · S&P 500 +22.0% · to Nov 19
Charles River Laboratories's Corp Strategy & Develop sold $73K of Charles River Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Since the trade +102.1% · S&P 500 +17.3% · to Nov 19
The CEO of Charles River Laboratories paid $1M out of pocket for Charles River Laboratories shares. 1 other person at Charles River Laboratories bought some too, in the same month.
Since the trade +102.1% · S&P 500 +17.3% · to Nov 19
Charles River Laboratories's Corporate Executive VP & COO paid $249K out of pocket for Charles River Laboratories shares. 1 other person at Charles River Laboratories bought some too, in the same month.
Traded Feb 20, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +102.1% · S&P 500 +17.3% · to Nov 19
Charles River Laboratories's Corp Strategy & Develop sold $715K of Charles River Laboratories shares. The filing does not indicate a pre-arranged trading plan.
1 open-market purchase and 21 open-market sales by insiders of CRL between Jan 19, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 4, 2026. The data provider lists the next release for Feb 16, 2027; that date may change.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
James C Foster, Director, Oct 22, 2026, about $8.41M. Sold 13 days before the company's next earnings release on 2026-11-04Form 4
Shannon M Parisotto, CEVP, Disc & Safety Assessment, Oct 21, 2026, about $743K. Sold 14 days before the company's next earnings release on 2026-11-04Form 4
Shannon M Parisotto, CEVP, Disc & Safety Assessment, Oct 5, 2026, about $303K. Sold 30 days before the company's next earnings release on 2026-11-04Form 4
James C Foster, Director, Aug 25, 2026, about $10.1M. Sold 20 days after the company's previous earnings release on 2026-08-05Form 4
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
Shannon M Parisotto, CEVP, Disc & Safety Assessment, Aug 19, 2026, about $600K. Sold 14 days after the company's previous earnings release on 2026-08-05
Nancy C Andrews, Director, Aug 18, 2026, about $163K. Sold 13 days after the company's previous earnings release on 2026-08-05Form 4
Birgit Girshick, Chief Executive Officer, Aug 11, 2026, about $1.82M. Sold 6 days after the company's previous earnings release on 2026-08-05Form 4
Shannon M Parisotto, CEVP, Disc & Safety Assessment, Aug 11, 2026, about $1.04M. Sold 6 days after the company's previous earnings release on 2026-08-05Form 4
James C Foster, Director, Aug 10, 2026, about $7.9M. Sold 5 days after the company's previous earnings release on 2026-08-05Form 4
Michael Gunnar Knell, SVP, Finance and CAO, Aug 6, 2026, about $330K. Sold 1 day after the company's previous earnings release on 2026-08-05Form 4